• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Azor (amlodipine besylate; olmesartan medoxomil)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Azor (amlodipine besylate; olmesartan medoxomil)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Azor is a combination of the angiotensin II receptor antagonist olmesartan, and the calcium channel blocker amlodipine. The amlodipine component of Azor inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, and the olmesartan medoxomil component of Azor blocks the vasoconstrictor effects of angiotensin II.

    Azor is specifically indicated for the treatment of hypertension, alone or with other antihypertensive agents.

    Azor is supplied as a tablet designed for oral administration. The drug comes in four strengths; the amlodipine dose is listed first and the olmesartan dose is listed second (both in mg): 5/20, 5/40, 10/20 and 10/40. The dosage may be increased after two weeks. The maximum recommended dose of Azor is 10/40.

    Clinical Results

    FDA Approval
    FDA approval of Azor was based on the results of several clinical trials.

    Azor
    An 8-week, multi-center, double-blind, randomized, placebo controlled, parallel group, factorial study enrolled 1,940 subjects with mild to severe hypertension. The subjects were placed in one of 12 treatment arms to receive placebo, monotherapy treatment with amlodipine 5 mg or 10 mg, monotherapy treatment with olmesartan medoxomil 10 mg, 20 mg, or 40 mg, or combination therapy with amlodipine/olmesartan medoxomil (Azor) at doses of 5/10 mg, 5/20 mg, 5/40 mg, 10/10 mg, 10/20 mg, and 10/40 mg. Results showed that all combinations produced greater mean reductions in blood pressure than either drug alone. The highest combination dose was amlodipine 10 mg plus 40 mg olmesartan. At this dose systolic blood pressure was cut by 30.1 mm Hg, a 53% greater drop than with 10 mg amlodipine alone. Diastolic blood pressure on this dose was reduced by 19 mm Hg, compared to 12.7 for amlodipine alone.

    Amlodipine
    The anti-hypertensive activity of amlodipine was evaluated in 15 double-blind, placebo-controlled, randomized studies. The trials enrolled a total of 1,338 subjects with mild to moderate hypertension who were treated with amoldipine or placebo once daily. Amoldipine resulted in statistically significant placebo-corrected reductions in supine and standing blood pressures at 24 hours postdose, averaging about 12/6 mmHg in the standing position and 13/7 mmHg in the supine position. Maintenance of the blood pressure effect over the 24-hour dosing interval was observed, with little difference in peak and trough effect.

    Olmesartan medoxomil
    The anti-hypertensive activity of olmesartan was evaluated in 7 placebo controlled studies. A total of 2,693 subjects with essential hypertension were enrolled and received placebo or olmesartan at doses ranging from 2.5 mg to 80 mg, for 6 to 12 weeks. The blood pressure lowering effect was maintained throughout the 24-hour period, with trough-to-peak ratios for systolic and diastolic response between 60% and 80%.

    Side Effects

    Side effects associated with the use of Azor may include, but are not limited to, the following:

    • Edema
    • Hypotension
    • Orthostatic Hypotension
    • Rash
    • Pruritus
    • Palpitation
    • Urinary Frequency
    • Nocturia

    Mechanism of Action

    Azor is a combination of the angiotensin II receptor antagonist olmesartan, and the calcium channel blocker amlodipine. The amlodipine component of Azor inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, and the olmesartan medoxomil component of Azor blocks the vasoconstrictor effects of angiotensin II.

    Literature References

    Chrysant SG, Marbury TC, Silfani TN Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Pressure Monitoring 2006 Jun;11(3):135-41

    Quan A, Chavanu K, Merkel J A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. American Journal of Cardiovascular Drugs : drugs, devices, and other interventions 2006;6(2):103-13

    Neutel JM, Smith DH, Silfani TN, Lee Y, Weber MA Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. Journal of Human Hypertension 2006 Apr;20(4):255-62

    Neutel JM, Smith DH, Weber MA, Wang AC, Masonson HN Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. Journal of Clinical Hypertension 2004 Apr;6(4):168-74

    Additional Information

    For additional information regarding Azor or hypertension, please visit the Azor web page.

    Approval Date: 2007-09-01
    Company Name: Daiichi Sankyo
    Back to Listings

    Upcoming Events

    • 15Apr

      Five Telltale Signs You’re Ready for an Electronic TMF System

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    • 06May

      The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Clinical-Trial-Brainstorming

      FDA, Industry Tackle Problem of Including Older Adults in Trials

    • ClinicalTrialNetwork-360x240.png

      National Community-Based Research Network Would Improve Reach of Trials

    • Bottleneck-360x240.png

      Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Genetic Research and IBC Oversight Requirements

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing